Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Calgary
$27,000.00
Combining Genetically Modified Hematopoietic Stem Cell Transplantation with Chimeric Antigen Receptor T Cell Therapy for Acute Myeloid Leukemia
EF 2025-26
Résumé
Acute Myeloid Leukemia (AML) is an aggressive cancer of the blood and bone marrow. The only established curative therapy for AML is a donor stem cell transplant, which relies on donor immune cells, called T cells, to kill the cancerous cells. Unfortunately, these same T cells attack the patients’ healthy organs, making the treatment risky for many patients. Relapse with AML remains common and the prognosis is poor, highlighting the need for safer and more targeted treatments such as chimeric antigen receptor (CAR) T cell therapy. CAR T cell therapy, which engineers a patient’s own T cells to recognize and kill cancer cells, has transformed the treatment of several blood cancers. For AML, however, CAR T therapy has been difficult to use safely because most targets on AML cells are also on healthy blood cells. As a result, CAR T cell therapy can also kill the patient’s healthy blood cells, causing dangerous side effects. One proposed strategy explored to avoid killing healthy cells is removing the target on transplanted blood-forming stem cells, so that healthy blood cells become invisible to the CAR T cells, while the cancer cells remain recognizable. Instead of removing the entire target, which risks dangerously disrupting the function of these cells, our project proposes editing the target on the blood-forming stem cells with precise genetic changes. These edits are designed to keep the cells working healthily while preventing CAR T cells from recognizing and attacking them. The edited stem cells would then rebuild the patients’ blood system to be protected, and the CAR T cells would eliminate the cancer. This strategy removes the need for risky, non-specific immune cell killing by combining CAR T cells with pure stem cell transplants.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
572704
Name
Imlach Camri B
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Combining Genetically Modified Hematopoietic Stem Cell Transplantation with Chimeric Antigen Receptor T Cell Therapy for Acute Myeloid Leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Acute Myeloid Leukemia; Base Editing; Chimeric Antigen Receptor T Cell Therapy; Epitope Editing; Hematopoietic Stem Cell Transplantation; Immunotherapy
Abstract
Acute Myeloid Leukemia (AML) is an aggressive cancer of the blood and bone marrow. The only established curative therapy for AML is a donor stem cell transplant, which relies on donor immune cells, called T cells, to kill the cancerous cells. Unfortunately, these same T cells attack the patients’ healthy organs, making the treatment risky for many patients. Relapse with AML remains common and the prognosis is poor, highlighting the need for safer and more targeted treatments such as chimeric antigen receptor (CAR) T cell therapy. CAR T cell therapy, which engineers a patient’s own T cells to recognize and kill cancer cells, has transformed the treatment of several blood cancers. For AML, however, CAR T therapy has been difficult to use safely because most targets on AML cells are also on healthy blood cells. As a result, CAR T cell therapy can also kill the patient’s healthy blood cells, causing dangerous side effects. One proposed strategy explored to avoid killing healthy cells is removing the target on transplanted blood-forming stem cells, so that healthy blood cells become invisible to the CAR T cells, while the cancer cells remain recognizable. Instead of removing the entire target, which risks dangerously disrupting the function of these cells, our project proposes editing the target on the blood-forming stem cells with precise genetic changes. These edits are designed to keep the cells working healthily while preventing CAR T cells from recognizing and attacking them. The edited stem cells would then rebuild the patients’ blood system to be protected, and the CAR T cells would eliminate the cancer. This strategy removes the need for risky, non-specific immune cell killing by combining CAR T cells with pure stem cell transplants.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Imlach, Camri B
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~